Your browser doesn't support javascript.
loading
The molecular landscape of well differentiated retroperitoneal liposarcoma.
Tyler, Robert; Dilworth, Mark P; James, Jonathan; Blakeway, Daniel; Stockton, Joanne D; Morton, Dion G; Taniere, Phillipe; Gourevitch, David; Desai, Anant; Beggs, Andrew D.
Afiliación
  • Tyler R; Institute of Cancer and Genomic Medicine, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
  • Dilworth MP; Institute of Cancer and Genomic Medicine, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
  • James J; Institute of Cancer and Genomic Medicine, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
  • Blakeway D; Institute of Cancer and Genomic Medicine, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
  • Stockton JD; Institute of Cancer and Genomic Medicine, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
  • Morton DG; Institute of Cancer and Genomic Medicine, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
  • Taniere P; Midland Abdominal Retroperitoneal Sarcoma Unit (MARSU), University Hospital Birmingham, Birmingham, UK.
  • Gourevitch D; Midland Abdominal Retroperitoneal Sarcoma Unit (MARSU), University Hospital Birmingham, Birmingham, UK.
  • Desai A; Midland Abdominal Retroperitoneal Sarcoma Unit (MARSU), University Hospital Birmingham, Birmingham, UK.
  • Beggs AD; Institute of Cancer and Genomic Medicine, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
J Pathol ; 255(2): 132-140, 2021 10.
Article en En | MEDLINE | ID: mdl-34156092
ABSTRACT
Well differentiated liposarcoma (WD-LPS) is a relatively rare tumour, with fewer than 50 cases occurring per year in the UK. These tumours are both chemotherapy- and radiotherapy-resistant and present a significant treatment challenge requiring radical surgery. Little is known of the molecular landscape of these tumours and no current targets for molecular therapy exist. We aimed to carry out a comprehensive molecular characterisation of WD-LPS via whole genome sequencing, RNA sequencing, and methylation array analysis. A recurrent mutation within exon 1 of FOXD4L3 was observed (chr970,918,189A>T; c.322A>T; p.Lys108Ter). Recurrent mutations were also observed in Wnt signalling, immunity, DNA repair, and hypoxia-associated genes. Recurrent amplification of HGMA2 was observed, although this was in fact part of a general amplification of the region around this gene. Recurrent gene fusions in HGMA2, SDHA, TSPAN31, and MDM2 were also observed as well as consistent rearrangements between chromosome 6 and chromosome 12. Our study has demonstrated a recurrent mutation within FOXD4L3, which shows evidence of interaction with the PAX pathway to promote tumourigenesis. © 2021 The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd. on behalf of The Pathological Society of Great Britain and Ireland.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Retroperitoneales / Factores de Transcripción Forkhead / Liposarcoma Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Pathol Año: 2021 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Retroperitoneales / Factores de Transcripción Forkhead / Liposarcoma Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Pathol Año: 2021 Tipo del documento: Article País de afiliación: Reino Unido